Genetic Variation in Donor Ctla-4 Regulatory Region is Associated with Relapsed Free Survival and Overall Survival after Allogenieic Hematopoietic Cell Transplant
W. B. Clark,K. D. Gentry-Brown,D. C. Crawford,K-H Fan,H. Chen,B. N. Savani,A. Kassim,J. P. Greer,F. G. Schuening,B. G. Engelhardt,M. H. Jagasia
DOI: https://doi.org/10.1016/j.bbmt.2010.12.035
2011-01-01
Biology of Blood and Marrow Transplantation
Abstract:Relapse is a major cause of mortality after allogeneic hematopoietic cell transplant (allo-HCT). Graft-versus-tumor effect is mediated primarily by T-cells. CTLA-4 is a critical inhibitor of T-cell proliferation. Single nucleotide polymorphisms (SNPs) in CTLA-4 have been associated with various autoimmune disorders and solid organ allograft rejection. We hypothesized that genetic variation in donor CTLA-4 would impact relapse-free survival (RFS) and overall survival (OS) of recipients after allo-HCT independent of chronic graft-versus-host disease (cGVHD) status.Adult patients undergoing allo-HCT (cord transplant excluded) at a single center (1999-2008), with a minimum survival of 120 days, and with the availability of pre-transplant recipient and donor germline DNA samples were included (n = 164). Ten tagSNPs of the CTLA-4 gene (rs231775, rs231779, rs11571315, rs231777, rs3087243, rs16840252, rs231725, rs4553808, rs10197010, rs11571316) were identified using previously published criteria. All SNPs analyzed passed quality control [test of Hardy-Weinberg equilibrium (HWE) P > 0.001, MAF > 0.10, SNP call rate > 0.95, and pair-wise r2 value less than 0.8].Table 1 outlines the patient characteristics. In univariate analyses, the donor SNP rs4553808 A/A genotype was associated with improved RFS (P = 0.019) and OS (P = 0.033) compared to the A/G or G/G genotype. Multivariable analysis, adjusted for stem cell source (peripheral blood vs. bone marrow), GVHD subtype (classic/overlap vs. acute subtypes/none), and disease risk (low vs. intermediate vs. high) were performed to test the association of the significant SNPs with RFS and OS. rs4553808 A/A genotype (HR 2.44, P = 0.015), classic/overlap GVHD (HR 2.98, P = 0.002) and low/intermediate disease risk (HR 2.16, P = 0.03) were independent predictors of superior OS. rs4553808 A/A genotype (HR 2.39, P = 0.016), and classic/overlap GVHD (HR 3.84, P = 0.001) were independent predictors of superior RFS.Table 1Patient characteristics and survival of all patients. (N=164)VariableN(%)GVHD subtypeTotal Cohort (N=164)Classic plus Overlap cGVHD N(%) (N=101)aGVHD subtypes plus No GVHD N (%) (N=63)Age, median in years (range)47(18-69)49(21-67)46(18-69)GenderMale (R)80(49)49(49)31(49)Female (R)84(51)52(51)32(51)Female D to male R31(19)21(21)10(19)RaceCaucasian (R/D)156(95)/153(93)94(93)/92(91)62(98)/61(97)DiagnosisAcute Leukemia86(52)49(49)37(59)Chronic Leukemia19(12)11(11)8(13)Lymphoma54(33)38(37)16(25)other5(93)3(3)2(3)Disease Risk #Low65(40)38(38)27(43)Intermediate30(18)21(20)9(14)High40(24)25(25)15(24)Missing29(18)17(17)12(19)Stem Cell SourceMarrow44(27)23(22)21(33)Peripheral Blood120(73)78(78)42(67)Regimen IntensityMyeloablative111(68)69(68)42(67)Other53(32)32(32)21(33)Donor TypeRelated109(67)69(68)40(63)Unrelated55(33)32(32)23(37)HLA MatchHLA identical sibling108(66)68(67)40(63)HLA matched unrelated55(33)32(32)23(37)Other1(1)1(1)0GVHD ProphylaxisCSA/MTX112(68)72(71)40(63)CSA/MMF50(31)28(28)22(36)Other2(1)1(1)1(1)TBIYes79(48)52(51)27(43)No85(52)49(49)36(57)CMVR/D (+/+)63(38)35(34)28(44)R/D (+/-)19(12)12(12)7(11)R/D (-/+)49(29)29(29)18(29)R/D (-/-)35(21)25(25)10(16)Post-transplant CharacteristicsaGVHD€Grade 0-2 vs. 3-4179(78) vs. 32(20)78(77) vs. 21(21)51(81) vs. 11(7)Grade 0-1 vs. 2-439(24) vs. 122(74)39(24) vs. 75(74)15(24) vs. 47(75)PLT (X10(9)/L at day 100, median (range)110(10-356)105(17-244)112(10-356)Total Bilirubin (mg/dL) at day 100, median(range)0.8(0-3.6)0.8(0-2.4)0.9(0.2-3.6)Survival2 year OS: (95% CI)63%(56-72)73%(64-83)48%(36-64)2 year RFS¥: (95% CI)61%(54-70)73%(65-83)41%(30-57)# Disease risk-based on Committee of International Bone Marrow Transplant Registry (CIBMTR) risk criteria; € aGVHD-3 cases missing; ¥ RFS analyses includes death from non-relapse causes as competing risk. GVHD-graft-versus-host disease; cGVHD-chronic GVHD; aGVHD-acute GVHD; R-recipient; D-donor; HLA-Human Leukocyte Antigen; CSA-cyclosporine; MTX-methotrexate; MMF-mycophenolate moefitil; TBI-Total body irradiation; CMV-cytomegalovirus; PLT-platelet; OS-overall survival; RFS-relapse free survival; CI-confidence interval. Open table in a new tab Relapse is a major cause of mortality after allogeneic hematopoietic cell transplant (allo-HCT). Graft-versus-tumor effect is mediated primarily by T-cells. CTLA-4 is a critical inhibitor of T-cell proliferation. Single nucleotide polymorphisms (SNPs) in CTLA-4 have been associated with various autoimmune disorders and solid organ allograft rejection. We hypothesized that genetic variation in donor CTLA-4 would impact relapse-free survival (RFS) and overall survival (OS) of recipients after allo-HCT independent of chronic graft-versus-host disease (cGVHD) status. Adult patients undergoing allo-HCT (cord transplant excluded) at a single center (1999-2008), with a minimum survival of 120 days, and with the availability of pre-transplant recipient and donor germline DNA samples were included (n = 164). Ten tagSNPs of the CTLA-4 gene (rs231775, rs231779, rs11571315, rs231777, rs3087243, rs16840252, rs231725, rs4553808, rs10197010, rs11571316) were identified using previously published criteria. All SNPs analyzed passed quality control [test of Hardy-Weinberg equilibrium (HWE) P > 0.001, MAF > 0.10, SNP call rate > 0.95, and pair-wise r2 value less than 0.8]. Table 1 outlines the patient characteristics. In univariate analyses, the donor SNP rs4553808 A/A genotype was associated with improved RFS (P = 0.019) and OS (P = 0.033) compared to the A/G or G/G genotype. Multivariable analysis, adjusted for stem cell source (peripheral blood vs. bone marrow), GVHD subtype (classic/overlap vs. acute subtypes/none), and disease risk (low vs. intermediate vs. high) were performed to test the association of the significant SNPs with RFS and OS. rs4553808 A/A genotype (HR 2.44, P = 0.015), classic/overlap GVHD (HR 2.98, P = 0.002) and low/intermediate disease risk (HR 2.16, P = 0.03) were independent predictors of superior OS. rs4553808 A/A genotype (HR 2.39, P = 0.016), and classic/overlap GVHD (HR 3.84, P = 0.001) were independent predictors of superior RFS. # Disease risk-based on Committee of International Bone Marrow Transplant Registry (CIBMTR) risk criteria; € aGVHD-3 cases missing; ¥ RFS analyses includes death from non-relapse causes as competing risk. GVHD-graft-versus-host disease; cGVHD-chronic GVHD; aGVHD-acute GVHD; R-recipient; D-donor; HLA-Human Leukocyte Antigen; CSA-cyclosporine; MTX-methotrexate; MMF-mycophenolate moefitil; TBI-Total body irradiation; CMV-cytomegalovirus; PLT-platelet; OS-overall survival; RFS-relapse free survival; CI-confidence interval.